{
  "context": {
    "rules": [
      "Rule1: Either the trial coordinator administers the placebo or the trial is successful.",
      "Rule2: If the patient reports an adverse event, then, provided that the drug passes the efficacy check, the trial is successful.",
      "Rule3: If the patient is enrolled in the trial, then either the patient withdraws from the trial or the patient reports an adverse event.",
      "Rule4: Under the condition that the patient receives medical monitoring, the patient receives compensation.",
      "Rule5: In the event that the trial achieves its primary endpoint, the trial achieves its secondary endpoint.",
      "Rule6: If the researcher publishes the results, then, provided that the trial achieves its secondary endpoint, the patient shows improvement.",
      "Rule7: Whenever the researcher presents at a conference, then, under the condition that the trial achieves its secondary endpoint, the patient shows improvement.",
      "Rule8: Provided that the trial coordinator administers the experimental drug, it is not the case that the trial coordinator administers the placebo.",
      "Rule9: If the company licenses the technology, then the company files a patent or the researcher publishes the results or the researcher presents at a conference.",
      "Rule10: Either the company licenses the technology or the pharma giant acquires the company.",
      "Rule11: Provided that the pharma giant acquires the company, the pharma giant markets the drug.",
      "Rule12: Whenever the pharma giant markets the drug, the company files a patent or the researcher publishes the results or the researcher presents at a conference.",
      "Rule13: If the ethics board halts the trial, then, given that the trial coordinator does not administer the experimental drug, the patient experiences a side effect.",
      "Rule14: Either the ethics board halts the trial or the data safety monitor halts the trial.",
      "Rule15: The staff member violates the protocol or, if the data safety monitor halts the trial, then, given that the trial coordinator does not administer the experimental drug, the patient experiences a side effect.",
      "Rule16: Provided that the advisory committee recommends approval, then, whenever the trial coordinator does not administer the experimental drug, the patient experiences a side effect.",
      "Rule17: Either the advisory committee recommends approval or the regulatory consultant recommends approval.",
      "Rule18: If the company submits an application, then, provided that the regulatory consultant recommends approval, whenever the trial coordinator does not administer the experimental drug, the patient experiences a side effect.",
      "Rule19: The company submits an application or the researcher submits an application.",
      "Rule20: Whenever the researcher submits an application, then, given that the regulatory consultant recommends approval, under the condition that the trial coordinator does not administer the experimental drug, the patient experiences a side effect.",
      "Rule21: Provided that the biostatistician conducts an analysis, the trial shows statistical significance.",
      "Rule22: The biostatistician conducts an analysis or the data auditor detects an anomaly.",
      "Rule23: Under the condition that the lab technician tests purity, the drug passes quality control.",
      "Rule24: The lab technician tests purity or the lab technician tests stability.",
      "Rule25: Whenever the lab technician tests stability, the lab technician confirms specifications.",
      "Rule26: If the FDA receives approval for the trial, then the trial meets endpoint criteria.",
      "Rule27: Given that the FDA receives approval for the trial, the trial receives funding.",
      "Rule28: In the event that the FDA receives approval for the trial, the trial does not receive funding.",
      "Rule29: The FDA receives approval for the trial or, provided that the trial coordinator does not administer the experimental drug, the patient experiences a side effect.",
      "Rule30: If the lab technician confirms specifications, then the FDA does not receive approval for the trial.",
      "Rule31: Either the whistleblower reports misconduct or the monitor reports misconduct.",
      "Rule32: Under the condition that the monitor reports misconduct, the patient does not drop out.",
      "Rule33: If the regulator initiates an audit, then, given that the whistleblower reports misconduct, the patient does not drop out.",
      "Rule34: The regulator initiates an audit or the sponsor initiates an audit.",
      "Rule35: Whenever the sponsor initiates an audit, then, provided that the whistleblower reports misconduct, the patient does not drop out.",
      "Rule36: In the event that the company seeks partnership, the company files a patent.",
      "Rule37: Provided that the researcher seeks collaboration, the researcher publishes the results or the researcher presents at a conference.",
      "Rule38: If the data scientist analyzes data, then the company seeks partnership or the researcher seeks collaboration.",
      "Rule39: Under the condition that the company launches the drug, the drug generates revenue.",
      "Rule40: The company launches the drug or, if the pharma giant acquires the company, then the company files a patent or the researcher publishes the results or the researcher presents at a conference.",
      "Rule41: Provided that the manufacturer recalls the drug, the drug does not generate revenue.",
      "Rule42: Either the manufacturer recalls the drug or the regulator recalls the drug.",
      "Rule43: Whenever the regulator recalls the drug, the drug does not generate revenue.",
      "Rule44: If the patient shows deterioration, then the patient does not show no change.",
      "Rule45: Given that the drug passes the safety check, the trial is successful.",
      "Rule46: Either the drug passes the safety check or the drug passes the efficacy check.",
      "Rule47: If the patient withdraws from the trial, then the patient completes the trial.",
      "Rule48: If it is not the case that, if the staff member violates the protocol then the staff member receives a warning, then the staff member faces termination.",
      "Rule49: Provided that it is not the case that, if the data auditor detects an anomaly then the trial does not meet endpoint criteria, the data auditor triggers an investigation.",
      "Rule50: If it is not the case that the patient withdraws from the trial or the patient reports an adverse event, then the patient drops out.",
      "Rule51: Given that it is not the case that, if the trial is not successful then the patient shows improvement, the patient shows no change.",
      "Rule52: Under the condition that it is not the case that, if the trial is not successful then the patient shows improvement, the patient shows deterioration.",
      "Rule53: Provided that the patient is not enrolled in the trial, the patient receives medical monitoring.",
      "Rule54: If the trial coordinator does not administer the experimental drug, then the patient does not experience a side effect.",
      "Rule55: Under the condition that the trial is not successful, the trial achieves its primary endpoint."
    ],
    "facts": [
      "Fact1: The data scientist analyzes data.",
      "Fact2: The patient does not receive compensation.",
      "Fact3: The patient does not show improvement.",
      "Fact4: The company does not file a patent.",
      "Fact5: The staff member does not receive a warning.",
      "Fact6: The staff member does not face termination.",
      "Fact7: The trial does not show statistical significance.",
      "Fact8: The data auditor does not trigger an investigation.",
      "Fact9: The drug does not pass quality control.",
      "Fact10: The patient does not complete the trial."
    ]
  },
  "question": "The trial is successful."
}